Theravance Biopharma, Inc. News Releases https://investor.theravance.com/ Theravance Biopharma, Inc. News Releases en Theravance Biopharma Reports Data from Phase 1b Study of TD-1473 in Oral Presentation at Digestive Disease Week (DDW) 2019 https://investor.theravance.com/news-releases/news-release-details/theravance-biopharma-reports-data-phase-1b-study-td-1473-oral Data Demonstrate Signals of Clinical, Histologic and Biomarker Activity Suggesting Localized Target Engagement following Four Weeks of Treatment in Patients with Moderately-to-Severely Active Ulcerative Colitis Additional Findings Demonstrate Minimal Systemic Exposure and No Evidence of Systemic Tue, 21 May 2019 07:01:00 -0400 Theravance Biopharma, Inc. News Releases 11136 Theravance Biopharma and Mylan Present Additional YUPELRI® (revefenacin) Phase 3 Data Analysis at the 2019 ATS International Conference https://investor.theravance.com/news-releases/news-release-details/theravance-biopharma-and-mylan-present-additional-yupelrir-0 Post-Hoc Analysis Highlights the Potential Role of YUPELRI in the COPD Treatment Paradigm Additional Analyses Demonstrate Commitment to Further Scientific Understanding of COPD DUBLIN and HERTFORDSHIRE, England and PITTSBURGH , May 20, 2019 /PRNewswire/ -- Theravance Biopharma, Inc. Mon, 20 May 2019 10:15:00 -0400 Theravance Biopharma, Inc. News Releases 11126 Theravance Biopharma Announces Data from Phase 1b Study of TD-1473 to be Featured in Oral Presentation at Digestive Disease Week (DDW) 2019 https://investor.theravance.com/news-releases/news-release-details/theravance-biopharma-announces-data-phase-1b-study-td-1473-be Presentation to Highlight Positive Data Demonstrating Clinical and Biomarker Activity Suggesting Localized Target Engagement and Minimal Systemic Exposure Following Four Weeks of Treatment in Patients with Moderately-to-Severely Active Ulcerative Colitis DUBLIN , May 14, 2019 /PRNewswire/ -- Tue, 14 May 2019 08:30:00 -0400 Theravance Biopharma, Inc. News Releases 11106 Theravance Biopharma, Inc. Reports First Quarter 2019 Financial Results and Provides Business Update https://investor.theravance.com/news-releases/news-release-details/theravance-biopharma-inc-reports-first-quarter-2019-financial - Late-stage clinical studies of TD-1473 and ampreloxetine underway - Phase 1 results including biomarker data in asthmatics for lung-selective inhaled pan-JAK inhibitor TD-8236 expected in third quarter 2019 - Product launch of YUPELRI® (revefenacin) inhalation solution progressing in partnership Tue, 07 May 2019 16:05:00 -0400 Theravance Biopharma, Inc. News Releases 11091 Theravance Biopharma to Report First Quarter 2019 Financial Results on May 7 https://investor.theravance.com/news-releases/news-release-details/theravance-biopharma-report-first-quarter-2019-financial-results DUBLIN, Ireland , April 30, 2019 /PRNewswire/ --  Theravance Biopharma, Inc. (NASDAQ: TBPH) (" Theravance Biopharma " or the "Company") today announced that it will release financial results for the period ended March 31, 2019 and provide a business update after market close on Tuesday, May 7, 2019 Tue, 30 Apr 2019 16:05:00 -0400 Theravance Biopharma, Inc. News Releases 11026 Theravance Biopharma to Present at the 18th Annual Needham Healthcare Conference https://investor.theravance.com/news-releases/news-release-details/theravance-biopharma-present-18th-annual-needham-healthcare DUBLIN, Ireland , April 2, 2019 /PRNewswire/ --  Theravance Biopharma, Inc. (NASDAQ: TBPH) announced today that members of management will participate in a fireside chat at the 18 th Annual Needham Healthcare Conference on Tuesday, April 9, 2019 , at 9:20 a.m. ET . Tue, 02 Apr 2019 08:30:00 -0400 Theravance Biopharma, Inc. News Releases 10996 Theravance Biopharma Announces Ampreloxetine (TD-9855) Phase 2 Study Results Selected for Oral Presentation at 32nd European Neurology Congress https://investor.theravance.com/news-releases/news-release-details/theravance-biopharma-announces-ampreloxetine-td-9855-phase-2 Presentation to highlight data for novel, once-daily norepinephrine reuptake inhibitor in patients with neurogenic orthostatic hypotension 20-week data support previously-announced clinical observations after four weeks of treatment DUBLIN , March 25, 2019 /PRNewswire/ --  Theravance Biopharma, Mon, 25 Mar 2019 08:30:00 -0400 Theravance Biopharma, Inc. News Releases 10986 Theravance Biopharma Announces First Patient Dosed in Phase 2b/3 Study of TD-1473 in Patients with Ulcerative Colitis https://investor.theravance.com/news-releases/news-release-details/theravance-biopharma-announces-first-patient-dosed-phase-2b3 Induction and maintenance portions of study to evaluate gut-selective pan-JAK inhibitor in patients with moderately to severely active ulcerative colitis DUBLIN , March 12, 2019 /PRNewswire/ --  Theravance Biopharma, Inc. (NASDAQ: TBPH) (" Theravance Biopharma " or the "Company") today announced Tue, 12 Mar 2019 08:30:00 -0400 Theravance Biopharma, Inc. News Releases 10976 Theravance Biopharma, Inc. Reports Fourth Quarter and Full Year 2018 Financial Results and Provides Business Update https://investor.theravance.com/news-releases/news-release-details/theravance-biopharma-inc-reports-fourth-quarter-and-full-year-3 YUPELRI™ (revefenacin) inhalation solution product launch progressing in partnership with Mylan Ampreloxetine and TD-1473 late-stage clinical programs advancing DUBLIN , Feb. 26, 2019 /PRNewswire/ -- Theravance Biopharma, Inc. (" Theravance Biopharma " or the "Company") (NASDAQ: TBPH) today Tue, 26 Feb 2019 16:05:00 -0500 Theravance Biopharma, Inc. News Releases 10946 Theravance Biopharma to Present at the 8th Annual SVB Leerink Global Healthcare Conference https://investor.theravance.com/news-releases/news-release-details/theravance-biopharma-present-8th-annual-svb-leerink-global DUBLIN , Feb. 21, 2019 /PRNewswire/ --   Theravance Biopharma, Inc. (NASDAQ: TBPH) announced today that management will participate in a fireside chat at the 8 th Annual SVB Leerink Global Healthcare Conference on Thursday, February 28, 2019 , at 9:00 a.m. ET . Thu, 21 Feb 2019 08:30:00 -0500 Theravance Biopharma, Inc. News Releases 10881